Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Herpes Simplex Infections-Pipeline Review, H1 2015

Herpes Simplex Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Herpes Simplex Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Herpes Simplex Infections-Pipeline Review, H1 2015', provides an overview of the Herpes Simplex Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Herpes Simplex Infections Overview 9

Therapeutics Development 10

Pipeline Products for Herpes Simplex Infections-Overview 10

Pipeline Products for Herpes Simplex Infections-Comparative Analysis 11

Herpes Simplex Infections-Therapeutics under Development by Companies 12

Herpes Simplex Infections-Therapeutics under Investigation by Universities/Institutes 16

Herpes Simplex Infections-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Herpes Simplex Infections-Products under Development by Companies 20

Herpes Simplex Infections-Products under Investigation by Universities/Institutes 24

Herpes Simplex Infections-Companies Involved in Therapeutics Development 25

3-V Biosciences, Inc. 25

Adamis Pharmaceuticals Corporation 26

Admedus Ltd 27

Agenus, Inc. 28

AiCuris GmbH & Co. KG 29

AlphaVax, Inc. 30

Astellas Pharma Inc. 31

Beech Tree Labs, Inc. 32

BioApex, s.r.o. 33

CEL-SCI Corporation 34

Chimerix, Inc. 35

Colby Pharmaceutical Company 36

Epiphany Biosciences, Inc. 37

Foamix Pharmaceuticals Ltd. 38

Genocea Biosciences, Inc. 39

GenVec, Inc. 40

Immune Design Corp. 41

Immunovaccine, Inc. 42

Kala Pharmaceuticals, Inc. 43

Mymetics Corporation 44

NanoBio Corporation 45

NanoViricides, Inc. 46

NovaBay Pharmaceuticals, Inc. 47

Onxeo SA 48

Oryzon Genomics S.A. 49

Osel Inc. 50

PaxVax 51

Peregrine Pharmaceuticals, Inc. 52

Profectus BioSciences, Inc. 53

Romark Laboratories, L.C. 54

Sanofi 55

Sanofi Pasteur SA 56

Spider Biotech 57

Starpharma Holdings Limited 58

Vaccibody AS 59

Vaxart, Inc. 60

Vical Incorporated 61

Vironova AB 62

ViroStatics, srl 63

Herpes Simplex Infections-Therapeutics Assessment 64

Assessment by Monotherapy Products 64

Assessment by Combination Products 65

Assessment by Target 66

Assessment by Mechanism of Action 68

Assessment by Route of Administration 70

Assessment by Molecule Type 72

Drug Profiles 74

(celecoxib + famciclovir)-Drug Profile 74

acyclovir-Drug Profile 75

acyclovir-Drug Profile 76

acyclovir-Drug Profile 77

amenamevir-Drug Profile 78

Aspidasept-Drug Profile 79

astodrimer-Drug Profile 80

BA-368-Drug Profile 82

Biologic for Infectious Disease-Drug Profile 83

brincidofovir-Drug Profile 84

BTL-TMLHSV-Drug Profile 86

C-31G-Drug Profile 87

CEL-1000-Drug Profile 89

G-103-Drug Profile 91

GEN-002-Drug Profile 92

GEN-003-Drug Profile 93

genital herpes vaccine-Drug Profile 95

genital herpes vaccine [HSV-2]-Drug Profile 96

GV-2207-Drug Profile 97

HerpeCide-I-Drug Profile 98

herpes [Type-2] vaccine-Drug Profile 99

herpes simplex [HSV-2] vaccine-Drug Profile 100

herpes simplex vaccine-Drug Profile 101

herpes simplex vaccine-Drug Profile 102

herpes simplex virus [type 1, 2] vaccine-Drug Profile 103

herpes simplex virus [type 1] vaccine-Drug Profile 104

herpes simplex virus vaccine-Drug Profile 105

herpes simplex virus vaccine-Drug Profile 106

herpes simplex virus vaccine-Drug Profile 107

herpes simplex virus vaccine-Drug Profile 108

herpes simplex virus vaccine-Drug Profile 109

HSV [type 2] vaccine-Drug Profile 110

HSV vaccine-Drug Profile 111

HSV-529-Drug Profile 112

JVRS-100 + herpes simplex virus-2 vaccine-Drug Profile 114

Labyrinthopeptine A1-Drug Profile 115

MB-66-Drug Profile 116

Monoclonal Antibodies for HIV and Herpes Simplex Infections-Drug Profile 117

Monoclonal Antibody for Herpes Simplex Infections-Drug Profile 118

Monoclonal Antibody for Herpes Simplex Infections-Drug Profile 119

NVC-638-Drug Profile 120

NVC-704-Drug Profile 121

NVC-727-Drug Profile 122

PGN-632-Drug Profile 123

pritelivir-Drug Profile 124

RC-100b-Drug Profile 125

RKP-00156-Drug Profile 126

SB-105-Drug Profile 127

SB105-A10-Drug Profile 128

Small Molecule to Inhibit CDK9 for EBV and HSV Infections-Drug Profile 130

Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections-Drug Profile 131

Small Molecule to Inhibit LSD-1 for HSV-Drug Profile 132

Small Molecules for Bacterial and Viral Infections-Drug Profile 133

Small Molecules for Herpes Simplex and Hepatitis C Infections-Drug Profile 134

Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections-Drug Profile 135

Small Molecules for Viral Infections-Drug Profile 136

Synthetic Peptide for Oncology and Infectious Disease-Drug Profile 137

Synthetic Peptides for Influenza, HSV and HIV Infections-Drug Profile 138

Synthetic Peptides for Viral Infections-Drug Profile 139

UB-621-Drug Profile 140

valomaciclovir stearate-Drug Profile 141

VCLHB-01-Drug Profile 143

VCLHM-01-Drug Profile 144

VN-180-Drug Profile 145

Herpes Simplex Infections-Recent Pipeline Updates 146

Herpes Simplex Infections-Dormant Projects 170

Herpes Simplex Infections-Discontinued Products 174

Herpes Simplex Infections-Product Development Milestones 175

Featured News & Press Releases 175

Appendix 183

Methodology 183

Coverage 183

Secondary Research 183

Primary Research 183

Expert Panel Validation 183

Contact Us 183

Disclaimer 184

List of Tables

Number of Products under Development for Herpes Simplex Infections, H1 2015 14

Number of Products under Development for Herpes Simplex Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Herpes Simplex Infections-Pipeline by 3-V Biosciences, Inc., H1 2015 29

Herpes Simplex Infections-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 30

Herpes Simplex Infections-Pipeline by Admedus Ltd, H1 2015 31

Herpes Simplex Infections-Pipeline by Agenus, Inc., H1 2015 32

Herpes Simplex Infections-Pipeline by AiCuris GmbH & Co. KG, H1 2015 33

Herpes Simplex Infections-Pipeline by AlphaVax, Inc., H1 2015 34

Herpes Simplex Infections-Pipeline by Astellas Pharma Inc., H1 2015 35

Herpes Simplex Infections-Pipeline by Beech Tree Labs, Inc., H1 2015 36

Herpes Simplex Infections-Pipeline by BioApex, s.r.o., H1 2015 37

Herpes Simplex Infections-Pipeline by CEL-SCI Corporation, H1 2015 38

Herpes Simplex Infections-Pipeline by Chimerix, Inc., H1 2015 39

Herpes Simplex Infections-Pipeline by Colby Pharmaceutical Company, H1 2015 40

Herpes Simplex Infections-Pipeline by Epiphany Biosciences, Inc., H1 2015 41

Herpes Simplex Infections-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 42

Herpes Simplex Infections-Pipeline by Genocea Biosciences, Inc., H1 2015 43

Herpes Simplex Infections-Pipeline by GenVec, Inc., H1 2015 44

Herpes Simplex Infections-Pipeline by Immune Design Corp., H1 2015 45

Herpes Simplex Infections-Pipeline by Immunovaccine, Inc., H1 2015 46

Herpes Simplex Infections-Pipeline by Kala Pharmaceuticals, Inc., H1 2015 47

Herpes Simplex Infections-Pipeline by Mymetics Corporation, H1 2015 48

Herpes Simplex Infections-Pipeline by NanoBio Corporation, H1 2015 49

Herpes Simplex Infections-Pipeline by NanoViricides, Inc., H1 2015 50

Herpes Simplex Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 51

Herpes Simplex Infections-Pipeline by Onxeo SA, H1 2015 52

Herpes Simplex Infections-Pipeline by Oryzon Genomics S.A., H1 2015 53

Herpes Simplex Infections-Pipeline by Osel Inc., H1 2015 54

Herpes Simplex Infections-Pipeline by PaxVax, H1 2015 55

Herpes Simplex Infections-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 56

Herpes Simplex Infections-Pipeline by Profectus BioSciences, Inc., H1 2015 57

Herpes Simplex Infections-Pipeline by Romark Laboratories, L.C., H1 2015 58

Herpes Simplex Infections-Pipeline by Sanofi, H1 2015 59

Herpes Simplex Infections-Pipeline by Sanofi Pasteur SA, H1 2015 60

Herpes Simplex Infections-Pipeline by Spider Biotech, H1 2015 61

Herpes Simplex Infections-Pipeline by Starpharma Holdings Limited, H1 2015 62

Herpes Simplex Infections-Pipeline by Vaccibody AS, H1 2015 63

Herpes Simplex Infections-Pipeline by Vaxart, Inc., H1 2015 64

Herpes Simplex Infections-Pipeline by Vical Incorporated, H1 2015 65

Herpes Simplex Infections-Pipeline by Vironova AB, H1 2015 66

Herpes Simplex Infections-Pipeline by ViroStatics, srl, H1 2015 67

Assessment by Monotherapy Products, H1 2015 68

Assessment by Combination Products, H1 2015 69

Number of Products by Stage and Target, H1 2015 71

Number of Products by Stage and Mechanism of Action, H1 2015 73

Number of Products by Stage and Route of Administration, H1 2015 75

Number of Products by Stage and Molecule Type, H1 2015 77

Herpes Simplex Infections Therapeutics-Recent Pipeline Updates, H1 2015 150

Herpes Simplex Infections-Dormant Projects, H1 2015 174

Herpes Simplex Infections-Dormant Projects (Contd..1), H1 2015 175

Herpes Simplex Infections-Dormant Projects (Contd..2), H1 2015 176

Herpes Simplex Infections-Dormant Projects (Contd..3), H1 2015 177

Herpes Simplex Infections-Discontinued Products, H1 2015 178

List of Figures

Number of Products under Development for Herpes Simplex Infections, H1 2015 14

Number of Products under Development for Herpes Simplex Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 68

Assessment by Combination Products, H1 2015 69

Number of Products by Top 10 Targets, H1 2015 70

Number of Products by Stage and Top 10 Targets, H1 2015 70

Number of Products by Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72

Number of Products by Top 10 Routes of Administration, H1 2015 74

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 75

Number of Products by Top 10 Molecule Types, H1 2015 76

Number of Products by Stage and Top 10 Molecule Types, H1 2015 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

Adamis Pharmaceuticals Corporation

Admedus Ltd

Agenus, Inc.

AiCuris GmbH & Co. KG

AlphaVax, Inc.

Astellas Pharma Inc.

Beech Tree Labs, Inc.

BioApex, s.r.o.

CEL-SCI Corporation

Chimerix, Inc.

Colby Pharmaceutical Company

Epiphany Biosciences, Inc.

Foamix Pharmaceuticals Ltd.

Genocea Biosciences, Inc.

GenVec, Inc.

Immune Design Corp.

Immunovaccine, Inc.

Kala Pharmaceuticals, Inc.

Mymetics Corporation

NanoBio Corporation

NanoViricides, Inc.

NovaBay Pharmaceuticals, Inc.

Onxeo SA

Oryzon Genomics S.A.

Osel Inc.

PaxVax

Peregrine Pharmaceuticals, Inc.

Profectus BioSciences, Inc.

Romark Laboratories, L.C.

Sanofi

Sanofi Pasteur SA

Spider Biotech

Starpharma Holdings Limited

Vaccibody AS

Vaxart, Inc.

Vical Incorporated

Vironova AB

ViroStatics, srl

Herpes Simplex Infections Therapeutic Products under Development, Key Players in Herpes Simplex Infections Therapeutics, Herpes Simplex Infections Pipeline Overview, Herpes Simplex Infections Pipeline, Herpes Simplex Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com